A Phase II Study To Evaluate the Efficacy And Safety Of HRS-1301 In Participants With Dyslipidemia

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 189 participants.

Also called NCT07229937

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 189 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07229937
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07229937. Randomized; quadruple masking; primary purpose treatment. Start 2025-11-25 (actual); primary completion 2026-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase II Study To Evaluate the Efficacy And Safety Of HRS-1301 In Participants With Dyslipidemia
Condition
Hyperlipidemia
Intervention (Drug)
HRS-1301
Intervention (Drug)
HRS-1301
Intervention (Drug)
HRS-1301
Intervention (Drug)
HRS-1301
Intervention (Drug)
Placebo
Lead sponsor
Shandong Suncadia Medicine Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07229937
Content hash
b03ec627de950b2ca1bfbfba4f9cc117c7eb1aca6184c69ad5cdc4ba9cbc2cb4